Bio

Roy Amariglio, Ph.D., is a Principal on the Private Equity team. Prior to joining OrbiMed, Dr. Amariglio was a Director of Mergers Acquisitions and Licensing at Bayer Health Care where he was responsible for Health Care transactions. Prior to joining Bayer, he was a Summer Associate in the M&A group of Life Technologies (acquired by Thermo Fisher Scientific). Dr. Amariglio has published scientific articles on mechanisms of intracellular trafficking, bone and cartilage development and serum biomarkers in Xofigo patients. He received his B.A. in Chemistry and Biology from Tel Aviv University and M.Sc. and Ph.D. in Molecular Genetics from the Weizmann Institute in Israel. Dr. Amariglio also holds an MBA in Finance and Healthcare Management from the Wharton School of the University of Pennsylvania.